Notch- and vitamin D signaling in 1,25(OH)2D3-resistant glioblastoma multiforme (GBM) cell lines
Sandra Reichrath1, Cornelia S L Müller, Beate Gleissner
1Department of Internal Medicine I, The Saarland University Hospital, Homburg/Saar, Germany. inshes@uniklinikum-saarland.de
Abstract:
Recently, an important role of Notch activation for Ras-induced transformation of glial cells and for glioma growth and survival has been demonstrated. It was concluded that activation of Notch-signaling may represent a new target for glioblastoma multiforme (GBM) therapy. We now analyzed five GBM cell lines (Tx3095, Tx3868, U87, U118, U373) for key components of Notch-signaling pathways (Notch-1, Notch-2, Notch-3, Notch-4, Delta-like 1, Delta-like 3, Delta-like 4, Jagged-1, Jagged-2) using conventional RT-PCR. We found that some components (Notch-1, Notch-2, Notch-4, Jagged-1) were consistently expressed in all cell lines analyzed while, in contrast, other key components of Notch-signaling were differentially expressed. Notch-3 was expressed in three out of five cell lines (in U87, U118 and U373), but was missing in Tx3095 and Tx3868 cells. Jagged-2 was expressed in U87, U373 and Tx3868, but not in U118 or Tx3095 cells. Delta-like 1 and Delta-like 3 were not detected in Tx3905 cells, but in all other cell lines. RNA for Delta-like 4 was only found in U373 and Tx3868 GBM cell lines. Treating GBM cell lines with 1,25(OH)2D3 (10(-6), 10(-8), and 10(-10) M), the biologically active form of vitamin D, did not result in significant dose- or time-dependent antiproliferative effects, indicating that GBM cell lines are resistant against the antiproliferative activity of 1,25(OH)2D3. In vitro treatment of GBM cells with 1,25(OH)2D3 did not result in a modulation of the expression of key components of the Notch-signaling pathway. Treatment with HDAC-inhibitor TSA or DNA-methyltransferase inhibitor 5-aza exerted dose- and time-dependent antiproliferative effects on GBM cell lines. We asked the question whether the resistance against 1,25(OH)2D3 could be restored by co-treatment with TSA or 5-aza. However, combination therapy with 1,25(OH)2D3 and TSA or 5-aza did not result in enhanced antiproliferative effects as compared to treatment with TSA or 5-aza alone. In contrast, antiproliferative effects of TSA and 5-aza were partially antagonized by concomitant treatment with 1,25(OH)2D3, indicating a protective effect of 1,25(OH)2D3 against the antiproliferative effects of TSA and 5-aza in GBM cell lines. In conclusion, our findings point at a differential expression of key components of Notch-signaling in GBM cell lines that may be of importance for the growth characteristics of GBM. Our findings indicate that GBM cell lines are resistant against the antiproliferative effects of 1,25(OH)2D3, and that this resistance may not be overcome by modulation of epigenetic silencing. Our findings do not support the hypothesis that modulation of Notch-signaling pathways by 1,25(OH)2D3 may regulate growth of GBM cell lines.
Insights
Notch signaling components are differentially expressed in glioblastoma multiforme (GBM) cell lines. Vitamin D (1,25(OH)2D3) does not inhibit GBM cell proliferation and may protect against other therapies.
Area of Science:
- Neuro-oncology
- Molecular biology
- Cell signaling
Background:
- Notch signaling plays a crucial role in glial cell transformation and glioblastoma multiforme (GBM) growth.
- Notch activation is a potential therapeutic target for glioblastoma multiforme.
- Understanding Notch pathway component expression in GBM is vital for targeted therapy development.
Purpose of the Study:
- To analyze the expression of key Notch signaling pathway components in five human glioblastoma cell lines.
- To investigate the antiproliferative effects of 1,25(OH)2D3 (active vitamin D) on GBM cell lines.
- To determine if 1,25(OH)2D3 can overcome resistance to epigenetic modifiers (TSA, 5-aza) in GBM.
Main Methods:
- Conventional reverse transcription-polymerase chain reaction (RT-PCR) was used to assess Notch pathway component expression.
- Five human glioblastoma cell lines (Tx3095, Tx3868, U87, U118, U373) were analyzed.
- GBM cells were treated with varying doses of 1,25(OH)2D3, TSA, and 5-aza, individually and in combination.
Main Results:
- Differential expression of Notch signaling components (Notch-3, Jagged-2, Delta-like 1, 3, 4) was observed across GBM cell lines.
- GBM cell lines exhibited resistance to the antiproliferative effects of 1,25(OH)2D3.
- 1,25(OH)2D3 did not modulate Notch pathway component expression and partially antagonized the effects of TSA and 5-aza.
Conclusions:
- Differential Notch signaling component expression in GBM cell lines may influence their growth characteristics.
- GBM cell lines are resistant to 1,25(OH)2D3, and this resistance is not overcome by modulating epigenetic silencing.
- 1,25(OH)2D3 does not appear to regulate GBM cell growth via Notch signaling modulation and may have protective effects.
Related Concept Videos
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...


